2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 7.185

Change

-0.05 (-0.65)%

Market Cap

USD 1.14B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.06 (-0.11%)

USD 501.76B
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.06 (-0.11%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.15%)

USD 191.96B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.15%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.11%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.11%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.11%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.11%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.10 (-0.39%)

USD 157.79B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.10 (-0.39%)

USD 157.79B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.37% 40% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.37% 40% F 43% F
Trailing 12 Months  
Capital Gain 13.10% 43% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.10% 42% F 46% F
Trailing 5 Years  
Capital Gain 41.41% 58% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.41% 56% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 4.48% N/A N/A 48% F
Dividend Return 4.48% N/A N/A 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.61% N/A N/A 28% F
Risk Adjusted Return 20.72% N/A N/A 36% F
Market Capitalization 1.14B 80% B- 70% C-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike